<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370005</url>
  </required_header>
  <id_info>
    <org_study_id>1245.48</org_study_id>
    <secondary_id>2011-000347-25</secondary_id>
    <nct_id>NCT01370005</nct_id>
  </id_info>
  <brief_title>12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase III Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of BI 10773 (10 mg, 25 mg) Administered Orally, Once Daily Over 12 Weeks in Hypertensive Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This trial will evaluate safety and efficacy of BI 10773 in hypertensive patients with type 2
      diabetes. Since hyperglycaemia and hypertension are key risk factors for both micro- and
      macrovascular complications, assessment of both glucose and blood pressure lowering effects
      of BI 10773 in hypertensive patients with type 2 diabetes could provide clinically highly
      relevant, new information for the use of BI 10773
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in HbA1c after 12 weeks of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean 24-hour Systolic Blood Pressure Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline of mean 24-hour systolic blood pressure (SBP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean 24-hour Diastolic Blood Pressure Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in mean 24-hour diastolic blood pressure (DBP) after 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With HbA1c &lt;7%</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Proportion of patients with HbA1c &lt;7% after 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in FPG after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in body weight after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in daytime mean SBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in daytime mean DBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in nighttime mean SBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in nighttime mean DBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in Trough Mean Seated SBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in trough mean seated DBP after 12 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Reaching Blood Pressure &lt;130/80 mmHg</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Proportion of patients reaching blood pressure &lt;130/80 mmHg after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>A composite endpoint of the following conditions at week 12 compared to baseline (all 3 fulfilled): reduction of HbA1c from baseline of at least 0.5%, reduction of systolic blood pressure &gt; 3 mmHg from baseline and reduction of weight from baseline &gt; 2%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Orthostatic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Orthostatic blood pressure (BP) at baseline and after 12 weeks of treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Confirmed Hypoglycaemic Adverse Events</measure>
    <time_frame>From drug administration until last drug administration plus seven days, up to 171 days</time_frame>
    <description>Number of participants with confirmed hypoglycaemic adverse events</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>BI 10773 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 low dose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 10773 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 10773 high dose once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets matching BI 10773</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 high dose once daily</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 low dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 10773</intervention_name>
    <description>BI 10773 low dose once daily</description>
    <arm_group_label>BI 10773 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>BI 10773 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BI 10773 high dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Patients &gt;=18 years with type 2 diabetes

          2. HbA1c of &gt;= 7.0% (53 mmol/mol) and =&lt; 10% (86 mmol/mol)

          3. Mean seated systolic blood pressure 130-159 mmHg and diastolic blood pressure 80-99
             mmHg

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a glucose level &gt;240 mg/dl (&gt;13.3 mmol/L) after an
             overnight fast before randomization

          2. Known or suspected secondary hypertension

          3. Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or
             transient ischemic attack within 3 months prior to informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1245.48.10024 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>West Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edgewater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.10023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orchard</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.20003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Benesov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mlada Boleslav</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neratovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Opocno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pribram</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.42001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Slany</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsingør</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rødovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rødovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vaerløse</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.45007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vojens</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.37204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35805 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Joensuu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35806 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kouvola</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pori</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.35807 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bourges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tierce</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.33007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lüneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pirna</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Schkeuditz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Teuchern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.96003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baabda</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.96001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.96002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Etten Leur</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiderdorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Soerendonk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Spijkenisse</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Swifterbant</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Velp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Woerden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zijndrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.31017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Elverum</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kløfta</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sørumsand</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.47009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Härnösand</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Järfälla</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Skene</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1245.48.46001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lebanon</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2011</study_first_posted>
  <results_first_submitted>May 16, 2014</results_first_submitted>
  <results_first_submitted_qc>May 16, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>January 22, 2016</last_update_submitted>
  <last_update_submitted_qc>January 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Boehringer Ingelheim Policy on Transparency and Publication http://trials.boehringer-ingelheim.com/transparency_policy.html</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="276"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="256"/>
                <participants group_id="P2" count="265"/>
                <participants group_id="P3" count="266"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non compliant with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient refusal to continue,not due toAE</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason not defined above</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full analysis set (FAS) included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h SBP value. Treatment assignment as randomized</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="271"/>
            <count group_id="B2" value="276"/>
            <count group_id="B3" value="276"/>
            <count group_id="B4" value="823"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="8.8"/>
                    <measurement group_id="B2" value="60.6" spread="8.5"/>
                    <measurement group_id="B3" value="59.9" spread="9.7"/>
                    <measurement group_id="B4" value="60.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1c Change From Baseline</title>
        <description>Change from baseline in HbA1c after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS), which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline</title>
          <description>Change from baseline in HbA1c after 12 weeks of treatment.</description>
          <population>Full analysis set (FAS), which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and last observation carried forward (LOCF) was used for imputation of missing values.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.60"/>
                    <measurement group_id="O2" value="-0.59" spread="0.63"/>
                    <measurement group_id="O3" value="-0.63" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes baseline HbA1c as lin. covariate and treatment, baseline renal function, region and baseline N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>-0.52</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes baseline HbA1c as lin. covariate and treatment, baseline renal function, region and baseline N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean 24-hour Systolic Blood Pressure Change From Baseline</title>
        <description>Change from baseline of mean 24-hour systolic blood pressure (SBP).</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS, which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-hour Systolic Blood Pressure Change From Baseline</title>
          <description>Change from baseline of mean 24-hour systolic blood pressure (SBP).</description>
          <population>FAS, which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="8.25"/>
                    <measurement group_id="O2" value="-2.99" spread="8.86"/>
                    <measurement group_id="O3" value="-3.59" spread="9.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model incl. baseline (bl) HbA1c, bl mean 24h SBP as lin. covariates; treatment, bl renal function, region, bl N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.44</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.69</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>-2.09</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model incl. baseline (bl) HbA1c, bl mean 24h SBP as lin. covariates; treatment, bl renal function, region, bl N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.68</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.50</ci_lower_limit>
            <ci_upper_limit>-2.83</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean 24-hour Diastolic Blood Pressure Change From Baseline</title>
        <description>Change from baseline in mean 24-hour diastolic blood pressure (DBP) after 12 weeks.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-hour Diastolic Blood Pressure Change From Baseline</title>
          <description>Change from baseline in mean 24-hour diastolic blood pressure (DBP) after 12 weeks.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c and a baseline mean 24-h systolic blood pressure value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="5.06"/>
                    <measurement group_id="O2" value="-1.10" spread="4.96"/>
                    <measurement group_id="O3" value="-1.32" spread="4.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model incl. baseline (bl) HbA1c, bl mean 24h DBP as lin. covariates; treatment, bl renal function, region, bl N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.15</ci_lower_limit>
            <ci_upper_limit>-0.56</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing structure was: 1) Change from baseline to week 12 in HbA1c, empa 25mg vs placebo 2) Change from baseline to week 12 in mean 24h SBP, empa 25mg vs placebo 3) Change from baseline to week 12 in HbA1c, empa 10mg vs placebo 4) Change from baseline in mean 24h SBP, empa 10mg vs placebo 5) Change from baseline in mean 24h DBP, empa 25mg vs placebo 6) Change from baseline in mean 24h DBP empa 10mg vs placebo.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Hierarchical testing, no adjustment of p-values.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model incl. baseline (bl) HbA1c, bl mean 24h DBP as lin. covariates; treatment, bl renal function, region, bl N of antihyperten. med. as fixed effects</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.51</ci_lower_limit>
            <ci_upper_limit>-0.93</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With HbA1c &lt;7%</title>
        <description>Proportion of patients with HbA1c &lt;7% after 12 weeks.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Patients in the full analysis set (FAS) and with baseline HbA1c &gt;= 7%. Treatment assignment as randomised.
Non-completers (missing data due to early discontinuation or values after start of rescue medication) considered 'failure' was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With HbA1c &lt;7%</title>
          <description>Proportion of patients with HbA1c &lt;7% after 12 weeks.</description>
          <population>Patients in the full analysis set (FAS) and with baseline HbA1c &gt;= 7%. Treatment assignment as randomised.
Non-completers (missing data due to early discontinuation or values after start of rescue medication) considered 'failure' was used as the imputation rule.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="252"/>
                <count group_id="O2" value="256"/>
                <count group_id="O3" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment, baseline renal function, region, baseline number of antihypertensive medications and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.51</ci_lower_limit>
            <ci_upper_limit>11.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment, baseline renal function, region, baseline number of antihypertensive medications and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.70</ci_lower_limit>
            <ci_upper_limit>11.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
        <description>Change from baseline in FPG after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline</title>
          <description>Change from baseline in FPG after 12 weeks of treatment.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" spread="38.29"/>
                    <measurement group_id="O2" value="-15.23" spread="33.32"/>
                    <measurement group_id="O3" value="-24.45" spread="35.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline FPG</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.63</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.91</ci_lower_limit>
            <ci_upper_limit>-18.60</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline FPG</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-30.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.61</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.32</ci_lower_limit>
            <ci_upper_limit>-25.08</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight Change From Baseline</title>
        <description>Change from baseline in body weight after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight Change From Baseline</title>
          <description>Change from baseline in body weight after 12 weeks of treatment.</description>
          <population>Full analysis set (FAS) which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="1.55"/>
                    <measurement group_id="O2" value="-1.67" spread="2.38"/>
                    <measurement group_id="O3" value="-2.16" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline number of antihypertensive med., baseline HbA1c and baseline weight</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline number of antihypertensive med., baseline HbA1c and baseline weight</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.33</ci_lower_limit>
            <ci_upper_limit>-1.62</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline</title>
        <description>Change from baseline in daytime mean SBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Mean Systolic Blood Pressure (SBP) Change From Baseline</title>
          <description>Change from baseline in daytime mean SBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="8.74"/>
                    <measurement group_id="O2" value="-3.40" spread="9.55"/>
                    <measurement group_id="O3" value="-4.12" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, N of antihypertensive medications, baseline HbA1c and baseline daytime SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.94</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.73</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.37</ci_lower_limit>
            <ci_upper_limit>-2.52</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline daytime SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.20</ci_lower_limit>
            <ci_upper_limit>-3.36</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline</title>
        <description>Change from baseline in daytime mean DBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Mean Diastolic Blood Pressure (DBP) Change From Baseline</title>
          <description>Change from baseline in daytime mean DBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="5.36"/>
                    <measurement group_id="O2" value="-1.28" spread="5.41"/>
                    <measurement group_id="O3" value="-1.58" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline daytime DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.56</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline daytime DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.98</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.44</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>-1.12</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline</title>
        <description>Change from baseline in nighttime mean SBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nighttime Mean Systolic Blood Pressure (SBP) Change From Baseline</title>
          <description>Change from baseline in nighttime mean SBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="10.22"/>
                    <measurement group_id="O2" value="-2.22" spread="10.21"/>
                    <measurement group_id="O3" value="-2.47" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline night-time SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.09</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline night-time SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.90</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.48</ci_lower_limit>
            <ci_upper_limit>-1.32</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline</title>
        <description>Change from baseline in nighttime mean DBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Nighttime Mean Diastolic Blood Pressure (DBP) Change From Baseline</title>
          <description>Change from baseline in nighttime mean DBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="6.80"/>
                    <measurement group_id="O2" value="-0.80" spread="6.21"/>
                    <measurement group_id="O3" value="-0.75" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0566</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline night-time DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.95</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.93</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0208</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline night-time DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.12</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline</title>
        <description>Change from baseline in Trough Mean Seated SBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Mean Seated Systolic Blood Pressure (SBP) Change From Baseline</title>
          <description>Change from baseline in Trough Mean Seated SBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="11.92"/>
                    <measurement group_id="O2" value="-4.73" spread="12.54"/>
                    <measurement group_id="O3" value="-5.45" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline seated SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.99</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.86</ci_lower_limit>
            <ci_upper_limit>-1.98</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline seated SBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.98</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.73</ci_lower_limit>
            <ci_upper_limit>-2.87</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline</title>
        <description>Change from baseline in trough mean seated DBP after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Mean Seated Diastolic Blood Pressure (DBP) Change From Baseline</title>
          <description>Change from baseline in trough mean seated DBP after 12 weeks of treatment.</description>
          <population>FAS which included all randomised and treated patients who had a baseline HbA1c value and a baseline mean 24-h systolic blood pressure (SBP) value. Treatment assignment as randomised.
Values after start of antidiabetic rescue therapy or change of antihypertensive therapy were set to missing and LOCF was used for imputation of missing values.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.02" spread="6.58"/>
                    <measurement group_id="O2" value="-3.18" spread="7.10"/>
                    <measurement group_id="O3" value="-3.01" spread="7.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline seated DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.01</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 10mg minus placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment, baseline renal function, geographical region, baseline N of antihyperten. med., baseline HbA1c and baseline seated DBP</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.55</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.97</ci_lower_limit>
            <ci_upper_limit>-0.82</ci_upper_limit>
            <estimate_desc>Difference calculated as empa 25mg minus placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Reaching Blood Pressure &lt;130/80 mmHg</title>
        <description>Proportion of patients reaching blood pressure &lt;130/80 mmHg after 12 weeks of treatment</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Patients in the FAS without blood pressure control at baseline. Blood pressure control is defined as DBP&lt;80 mmHg and SBP &lt;130 mmHg. Treatment assignment as randomised.
Non-completers (missing data due to early disc, values after start of rescue medication or changes in antihyp. therapy) considered 'failure' was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Reaching Blood Pressure &lt;130/80 mmHg</title>
          <description>Proportion of patients reaching blood pressure &lt;130/80 mmHg after 12 weeks of treatment</description>
          <population>Patients in the FAS without blood pressure control at baseline. Blood pressure control is defined as DBP&lt;80 mmHg and SBP &lt;130 mmHg. Treatment assignment as randomised.
Non-completers (missing data due to early disc, values after start of rescue medication or changes in antihyp. therapy) considered 'failure' was used as the imputation rule.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="251"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0021</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment, baseline renal function, region, baseline number of antihypertensive medications and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.39</ci_lower_limit>
            <ci_upper_limit>4.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment, baseline renal function, region, baseline number of antihypertensive medications and baseline HbA1c</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>3.96</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight</title>
        <description>A composite endpoint of the following conditions at week 12 compared to baseline (all 3 fulfilled): reduction of HbA1c from baseline of at least 0.5%, reduction of systolic blood pressure &gt; 3 mmHg from baseline and reduction of weight from baseline &gt; 2%</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Patients in the full analysis set (FAS). Treatment assignment as randomised.
Non-completers (missing data due to early discontinuation, values after start of rescue medication or changes in antihypertensive therapy) considered 'failure' was used as the imputation rule.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Change From Baseline of HbA1c, Systolic Blood Pressure and Body Weight</title>
          <description>A composite endpoint of the following conditions at week 12 compared to baseline (all 3 fulfilled): reduction of HbA1c from baseline of at least 0.5%, reduction of systolic blood pressure &gt; 3 mmHg from baseline and reduction of weight from baseline &gt; 2%</description>
          <population>Patients in the full analysis set (FAS). Treatment assignment as randomised.
Non-completers (missing data due to early discontinuation, values after start of rescue medication or changes in antihypertensive therapy) considered 'failure' was used as the imputation rule.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="271"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number fulfilled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number not fulfilled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="235"/>
                    <measurement group_id="O3" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Orthostatic Blood Pressure</title>
        <description>Orthostatic blood pressure (BP) at baseline and after 12 weeks of treatment.</description>
        <time_frame>Baseline and 12 weeks</time_frame>
        <population>Treated set for patients with available measurements at baseline and week 12. Treatment assignment as first medication taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Orthostatic Blood Pressure</title>
          <description>Orthostatic blood pressure (BP) at baseline and after 12 weeks of treatment.</description>
          <population>Treated set for patients with available measurements at baseline and week 12. Treatment assignment as first medication taken.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="219"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="192"/>
                    <measurement group_id="O3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Confirmed Hypoglycaemic Adverse Events</title>
        <description>Number of participants with confirmed hypoglycaemic adverse events</description>
        <time_frame>From drug administration until last drug administration plus seven days, up to 171 days</time_frame>
        <population>Treated set which included all patients treated with at least one dose of randomised trial medication. Treatment assignment as first medication taken.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Empa 10mg</title>
            <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Empa 25mg</title>
            <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Hypoglycaemic Adverse Events</title>
          <description>Number of participants with confirmed hypoglycaemic adverse events</description>
          <population>Treated set which included all patients treated with at least one dose of randomised trial medication. Treatment assignment as first medication taken.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="272"/>
                <count group_id="O2" value="276"/>
                <count group_id="O3" value="276"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until last drug administration plus seven days, up to 171 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>A placebo tablet, matching the empagliflozin 10mg and 25mg tablets, taken once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Empa 10mg</title>
          <description>Single oral dose of empagliflozin (empa) 10mg taken once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Empa 25mg</title>
          <description>Single oral dose of empagliflozin (empa) 25mg taken once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="276"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="272"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="276"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="276"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

